# Optimal Treatment Strategy Based on for Pediatric AML

> **NCT02848183** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 350 (—)

## Conditions studied

- Pediatric Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Idarubicin
- **DRUG:** Mitoxantrone
- **DRUG:** Etoposide
- **PROCEDURE:** Hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT02848183
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2020-12
- **Final completion:** —
- **Target enrollment:** 350 (—)
- **Last updated:** 2016-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02848183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02848183, "Optimal Treatment Strategy Based on for Pediatric AML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02848183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*